Skip to search formSkip to main contentSkip to account menu

Roniciclib

An orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Roniciclib selectively binds to and inhibits… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

BAY1000394
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Effects of roniciclib in preclinical models of anaplastic thyroid cancer
Many human cancers have altered cyclin-dependent kinase activity. Inhibition of cyclin-dependent kinases may arrest cell cycle… 
2017
2017
Abstract 2171: Multi-CDK inhibition efficiently suppresses AR function and cell growth in prostate cancer
Metastatic castration resistant prostate cancer (CRPC) continues to result in over 26,000 deaths per year in the United States… 
2016
2016
The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other…
Introduction. Copanlisib is a pan class-I PI3K inhibitor (i) with preferred activity towards PI3Kα and PI3Kδ that is currently in… 
2015
2015
3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)